Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report

Article Hematology

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Di Wang et al.

Summary: CT103A, a fully human BCMA-specific CAR T-cell therapy, has shown safety and high efficacy in patients with relapsed/refractory multiple myeloma, including those who had prior exposures to murine BCMA CAR therapy. Its overall response rate reaches 100%, with a significant portion achieving complete response or stringent complete response. Hematologic toxicities are common adverse events, but no immune effector cell-associated neurotoxicity syndrome was observed. Detection of CAR transgenes and median CAR transgene persistence support the potential of CT103A as a promising therapy for RRMM.

BLOOD (2021)

Add to Collection

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental